专家一致认为,预防,诊断和管理化学疗法引起的持续性脱毛症
Azael Freites-Martinez1, Zoe Apalla2, Jerry Shapiro3
1Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain.
Journal of the European Academy of Dermatology and Venereology : JEADV
|September 9, 2025
概括
建立了持续化疗诱导脱发症 (pCIA) 的指导方针,将其定义为化疗后持续超过六个月的脱发. 专家建议预防头皮冷却和早期干预使用米诺克西迪尔,同时建议乳腺癌患者不要服用某些药物.
科学领域:
- 皮瘤学 皮肤瘤学
- 头发疾病研究研究.
- 癌症的生存率 癌症的生存率
背景情况:
- 持续的化疗诱导性脱发症 (pCIA) 在癌症幸存者心理上产生重大影响.
- 目前缺乏用于pCIA诊断,预防和管理的标准化指南.
研究的目的:
- 建立基于共识的pCIA的定义.
- 开发pCIA的诊断标准和分级系统.
- 为pCIA.pCIA创建管理建议.
主要方法:
- 两轮的德尔菲方法与15名国际专家.
- 陈述以5点的利克特级别评分;强大的共识定义为≥75%的同意.
- 基于专家反的陈述的反复修订和重新评估.
主要成果:
- 47个声明 (75.8%) 达到了强烈的共识.
- pCIA被定义为无痕脱发症,在化疗后持续超过6个月.
- 塔克森,蒂奥特帕,人环素被确定为主要贡献者;建议预防头皮冷却;建议早期干预的米诺克西迪尔;对乳腺癌患者提醒的特定药物.
结论:
- 建立了对pCIA诊断和治疗的统一指南.
- 头皮冷却和及时干预可以改善癌症幸存者的结果.
- 需要对新疗法和长期化疗对毛囊的影响进行进一步的研究.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
597
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
597
Nursing Ethical Principles II
2.1K
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
2.1K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
817
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
817
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
606
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
606

